NIH wants to give Gilead a new, government subsidized monopoly on CAR T technology, this one for CD-30 proteins.
We have a briefing note on this license here: 2018: Briefing note on NIH proposed license to Gilead for CD-30 CAR T technology
2018: Briefing note on NIH proposed license to Gilead for CD-30 CAR T technology
Contact: Kim Treanor 202-332-2670; kim.treanor@keionline.org January 5, 2018 The National Institutes of Health (NIH) has proposed an exclusive license with Gilead for certain patent applications for inventions that target CD-30 proteins and CAR T technologies. The proposed license is to… Continue Reading
Chilean Cámara de Diputados Votes Overwhelmingly To Proceed With Compulsory Licenses for HCV Drugs
The Cámara de Diputados of the Chilean Congress has overwhelmingly passed a resolution calling on the President to advance the compulsory licensing request on HCV drugs made in March 2017 by patients, advocates including Innovarte NGO, and elected officials. The resolution, Number… Continue Reading
2017: National Institutes of Health proposed exclusive license for kidney cancer patents to company without its own phone number
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On November 29, 2017, the National Institutes of Health (NIH) has given a notice to a prospective license to patents on the treatment of renal cell carcinoma,… Continue Reading
SCP27: WIPO patent committee agrees to future work on patent oppositions, exceptions and limitations, and patents and health
On Friday afternoon, 15 December 2017, the 27th session of the WIPO Standing Committee on the Law of Patents (SCP) agreed to a future program of work that included the following topics: 1) Exceptions and Limitations to Patent Rights, 2)… Continue Reading
KEI reaction to 11th WTO Ministerial Conference – Joint Statement on E-Commerce
On December 13, 2017, a joint statement on e-commerce was endorsed by Ministers representing 70 WTO members at the 11th WTO Ministerial Conference in Buenos Aires, Argentina (see below). KEI’s statement on the WTO e-commerce agenda is as follows: “There… Continue Reading
SCP27: South Africa urges WIPO to invite UNHLP Co-Chairs to present their findings
On Tuesday, 12 December 2017, the South African delegation to the WIPO Standing Committee on the Law of Patents (SCP) delivered the following statement on patents and health. South Africa reiterated its strong support for the Report of the UN… Continue Reading
SCP27: KEI statement on pressures faced by Brazil and Colombia in using TRIPS flexibilities
On 12 December 2017, KEI delivered the following intervention to WIPO on pressures faced by Brazil and Colombia in using TRIPS flexibilities. 12 December 2017 SCP 27 Thank you Chair. We welcome the opportunity to provide inputs on the constraints… Continue Reading
SCP27: KEI statement on patents and health
On Tuesday, 12 December 2017, Knowledge Ecology International delivered the following intervention at the 27th session of the WIPO Standing Committee of the Law of Patents during discussions of a work program on patents and health. Knowledge Ecology International reiterates… Continue Reading
WIPO SCP27: KEI statement on exceptions and limitations to patent rights
On Monday, 11 December 2017, KEI delivered the following statement in response to WIPO’s publication of a Draft Reference Document on Exception Regarding Acts for Obtaining Regulatory Approval from Authorities. KEI commends the work of the WIPO secretariat in preparing… Continue Reading